A Retrospective Evaluation of Risk of Peripartum Cardiac Dysfunction in Survivors of Childhood, Adolescent and Young Adult Malignancies

Published on Jul 24, 2019in Cancers6.126
· DOI :10.3390/CANCERS11081046
Lori Chait-Rubinek1
Estimated H-index: 1
(ND: University of Notre Dame),
Justin A. Mariani23
Estimated H-index: 23
(Alfred Hospital)
+ 5 AuthorsBelinda A. Campbell16
Estimated H-index: 16
(Peter MacCallum Cancer Centre)
Sources
Abstract
Long-term survivors of childhood, adolescent and young adult (AYA) malignancies with past exposure to potentially cardiotoxic treatments are at risk of peripartum cardiac dysfunction. Incidence and risk factors for peripartum cardiac dysfunction and maternal cardiac outcomes in this population were investigated. Eligible long-term survivors were aged <30 years at cancer diagnosis, with ≥1 pregnancy occurring ≥5 years after diagnosis. “Peripartum” cardiac events were defined as occurring within pregnancy or ≤5months after delivery. Cardiac events were classified “symptomatic” or “subclinical”. “Peripartum cardiomyopathy” (PPCM) was defined as symptomatic dysfunction without prior cardiac dysfunction. Of 64 eligible women, 5 (7.8%) had peripartum cardiac events: 3 symptomatic, 2 subclinical. Of 110 live births, 2 (1.8%, 95% CI 0.2–6.4) were defined as PPCM: Significantly greater than the published general population incidence of 1:3000 (p < 0.001), representing a 55-fold (95% CI 6.6–192.0) increased risk. Risk factor analyses were hypothesis-generating, revealing younger age at cancer diagnosis and higher anthracycline dose. Postpartum, cardiac function of 4 women (80%) failed to return to baseline. In conclusion, peripartum cardiac dysfunction is an uncommon but potentially serious complication in long-term survivors of paediatric and AYA malignancies previously treated with cardiotoxic therapies. Peripartum cardiac assessment is strongly recommended for at-risk patients.
📖 Papers frequently viewed together
48 Citations
20185.74Cancer
9 Authors (Saro H. Armenian, ..., Smita Bhatia)
7 Citations
References18
Newest
#1José Luis ZamoranoH-Index: 82
#2Patrizio LancellottiH-Index: 109
Last. Thomas M. SuterH-Index: 39
view all 16 authors...
2-D : two-dimensional 3-D : three-dimensional 5-FU : 5-fluorouracil ACE : angiotensin-converting enzyme ARB : angiotensin II receptor blocker ASE : American Society of Echocardiography BNP : B-type natriuretic peptide CABG : coronary artery bypass graft CAD : coronary artery
965 CitationsSource
#1Melissa R. Hines (UNC: University of North Carolina at Chapel Hill)H-Index: 1
#2Daniel A. Mulrooney (UTHSC: University of Tennessee Health Science Center)H-Index: 32
Last. Monika L. Metzger (UTHSC: University of Tennessee Health Science Center)H-Index: 38
view all 8 authors...
Purpose Current information regarding pregnancy-associated cardiomyopathy among women treated for childhood cancer is insufficient to appropriately guide counseling and patient management. This study aims to characterize its prevalence within a large cohort of females exposed to cardiotoxic therapy.
22 CitationsSource
#1John D. Groarke (Brigham and Women's Hospital)H-Index: 23
#2Anju Nohria (Brigham and Women's Hospital)H-Index: 39
Anthracyclines are potent anti-neoplastic agents with proven efficacy in the treatment of many pediatric and adult hematologic and solid organ cancers. Dose-dependent anthracycline induced cardiomyopathy is the most notorious and well-studied chemotherapy-induced cardiovascular toxicity that was first described in 1971 in 67 patients treated with adriamycin for a variety of tumors.1 The clinical significance of anthracycline cardiotoxicity is growing with increasing cancer survivorship and incre...
41 CitationsSource
#1Jennifer Lewey (CUMC: Columbia University Medical Center)H-Index: 10
#2Jennifer Haythe (CUMC: Columbia University Medical Center)H-Index: 5
Cardiomyopathy during pregnancy is uncommon but potentially catastrophic to maternal health, accounting for up to 11% of maternal deaths. Peripartum cardiomyopathy is diagnosed in women without a history of heart disease 1 month before delivery or within 5 months postpartum. About half of all women will have full myocardial recovery within 6 months of diagnosis, but complications such as severe heart failure or death are not rare. African-American women have higher rates of diagnosis and adverse...
17 CitationsSource
The number of women with heart disease who reach childbearing age in a good functional state increases continuously as advances in diagnosis and treatment improve overall health and prognosis. The cardiologist’s role is to give the woman an estimate of both maternal and fetal risk to allow her to make an informed decision about embarking on a pregnancy, and to provide appropriate antenatal care. There are only a few data about the natural history of anthracycline-induced cardiomyopathy during pr...
1 CitationsSource
#1Stephen A. FeigH-Index: 33
#2Alan S. GamisH-Index: 39
Last. Wendy LandierH-Index: 37
view all 11 authors...
120 CitationsSource
#1Abboud J (WSU: Wayne State University)H-Index: 3
#2Yahya Murad (WSU: Wayne State University)H-Index: 1
Last. Tiziano M. Scarabelli (WSU: Wayne State University)H-Index: 23
view all 5 authors...
Abstract Peripartum cardiomyopathy (PPCM) is a rare disorder in which left ventricular dysfunction and symptoms of heart failure occur in the peripartum period in previously healthy women. Incidence of PPCM ranges from 1 in 1300 to 1 in 15,000 pregnancies. The etiology of PPCM is unknown, but viral, autoimmune, and idiopathic causes may contribute. The diagnostic criteria are onset of heart failure in the last month of pregnancy or in first 5 months postpartum, absence of determinable cause for ...
152 CitationsSource
#1Belinda A. Campbell (Peter MacCallum Cancer Centre)H-Index: 16
#2Greg Wheeler (Peter MacCallum Cancer Centre)H-Index: 14
Last. Natalie Goroncy (Peter MacCallum Cancer Centre)H-Index: 2
view all 5 authors...
Background. Long-term survivors of childhood malignancy are a newly emergent patient group with a unique but wide range of survivorship issues. There are rising demands for long-term, medical follow-up and social support for this potentially vulnerable group. These demands stem from improving survival rates and the progressively increasing incidence of late physical, psychological and social sequelae. Case-studies and Discussion. The ideal method to facilitate this long-term follow-up is unclear...
3 CitationsSource
#1Elvira C. van Dalen (UvA: University of Amsterdam)H-Index: 28
#2Helena J.H. van der Pal (UvA: University of Amsterdam)H-Index: 14
Last. Leontien C. M. Kremer (UvA: University of Amsterdam)H-Index: 52
view all 5 authors...
Abstract The cumulative incidence of anthracycline-induced clinical heart failure (A-CHF) in a large cohort of 830 children treated with a mean cumulative anthracycline dose of 288 mg/m 2 (median 280 mg/m 2 ; range 15–900 mg/m 2 ) with a very long and complete follow-up after the start of anthracycline therapy (mean 8.5 years; median 7.1 years; range 0.01–28.4 years) was 2.5%. A cumulative anthracycline dose of 300 mg/m 2 or more was the only independent risk factor (relative risk (RR) = 8). The...
213 CitationsSource
#1Elvira C. van Dalen (UvA: University of Amsterdam)H-Index: 28
#2Helena J.H. van der Pal (UvA: University of Amsterdam)H-Index: 14
Last. Leontien C. M. Kremer (UvA: University of Amsterdam)H-Index: 52
view all 6 authors...
Abstract The cumulative incidence of peripartum anthracycline-induced clinical heart failure (A-CHF) was evaluated in a cohort of 53 childhood cancer survivors who had delivered one or more children. None of them developed peripartum A-CHF (cumulative incidence 0%; 95% confidence interval (CI) 0–5.7%). The mean follow-up time after the first administration of anthracycline therapy was 20.3 years. They received a mean cumulative anthracycline dose of 267mg/m 2 . It is worth noticing that even 2 p...
48 CitationsSource
Cited By5
Newest
#1Hasan Ali FarhanH-Index: 3
Abstract null null Emerging role of novel and traditional biomarkers in the diagnosis and risk stratification of pregnant women with cardiovascular disease (CVD) are needed to raise the standard of care and optimizing management. Biomarkers that reliably distinguish women at high risk for complication would provide a novel biomarker-guided management approach and risk stratification strategy. The role of cardiac biomarkers during pregnancy remain a topic of interest and still need significant in...
Source
#2Wataru Shioyama (Shiga University of Medical Science)
Last. Jun YoshimatsuH-Index: 23
view all 4 authors...
Recent advances in cancer therapies have enabled many women diagnosed with malignancies during childhood and adolescence to survive longer and therefore to reach an age where they wish to conceive. When providing cancer treatment such as anticancer drugs and radiotherapy, attention is often paid to preserving future fertility, but little is known about maternal pregnancy risks, and in particular cardiovascular complications. Recent studies have shown that cardiovascular diseases such as cardiomy...
1 CitationsSource
#1Alexa C.O. Medica (UCSD: University of California, San Diego)H-Index: 3
#2Brian W. Whitcomb (UMass: University of Massachusetts Amherst)H-Index: 39
Last. H. Irene Su (UCSD: University of California, San Diego)H-Index: 21
view all 10 authors...
CONTEXT Although stages of reproductive aging for women in the general population are well described by STRAW+10 criteria, this is largely unknown for female adolescent and young adult cancer survivors (AYA survivors). OBJECTIVE This work aimed to evaluate applying STRAW + 10 criteria in AYA survivors using bleeding patterns with and without endocrine biomarkers, and to assess how cancer treatment gonadotoxicity is related to reproductive aging stage. DESIGN The sample (n = 338) included AYA sur...
Source
#1Kimberly K. Ma (UW: University of Washington)H-Index: 7
#2Sarah E. Monsell (UW: University of Washington)H-Index: 23
Last. Hilary S. Gammill (UW: University of Washington)H-Index: 13
view all 5 authors...
OBJECTIVE Cancer and pregnancy are likely increasing; however, updated estimates are needed to optimally address the unique needs of this patient population. The study aims to estimate the prevalence of cancer and cancer survivorship at delivery, to test the change in odds of cancer and cancer survivorship at delivery over the 10-year period, and to compare medical conditions, serious events, and obstetric complications between pregnancies with and without cancer at delivery. STUDY DESIGN We con...
1 CitationsSource
#3Candice K. Silversides (Mount Sinai Hospital)H-Index: 2
Abstract Background Cancer treatment can lead to left ventricular (LV) dysfunction in female cancer survivors of reproductive age, and pregnancy-related hemodynamic stress may result in LV dysfunction or heart failure (HF). Objectives The authors performed a systematic review and meta-analysis to determine the incidence of LV systolic dysfunction or HF during or soon after pregnancy in cancer survivors and evaluated the impact of history of cancer therapeutics-related cardiac dysfunction (CTRCD)...
2 CitationsSource